Low within-and between-day variability in exposure to new insulin glargine 300 U/ml

被引：0

作者：

Becker, R. H. ^{[1
]}

Nowotny, I. ^{[1
]}

Teichert, L. ^{[1
]}

Bergmann, K. ^{[1
]}

Kapitza, C. ^{[2
]}

机构：

[1] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

[2] Profil, Neuss, Germany

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

953

引用

页码：S390 / S390

页数：1

共 50 条

[41] Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives [J].

de Galan, Bastiaan E. .

PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :2097-2106

[42] THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND [J].

Koski, L. ;

Hahl, J. ;

Kaye, S. ;

Pousar, K. .

VALUE IN HEALTH, 2019, 22 :S596-S596

[43] Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial [J].

Bolli, Geremia B. ;

Cheng, Alice ;

Charbonnel, Bernard ;

Aroda, Vanita R. ;

Westerbacka, Jukka ;

Bosnyak, Zsolt ;

Boelle-Le Corfec, Emmanuelle ;

Rosenstock, Julio .

DIABETES OBESITY & METABOLISM, 2021, 23 (07) :1588-1593

[44] Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus [J].

Clements, Jennifer N. ;

Bello, Larkin .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (06) :359-366

[45] In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes [J].

Schiavon, Michele ;

Visentin, Roberto ;

Giegerich, Clemens ;

Sieber, Jochen ;

Dalla Man, Chiara ;

Cobelli, Claudio ;

Klabunde, Thomas .

DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) :553-561

[46] Lower Glucose Variability and Risk for Hypoglycemia on Glargine 300 U/mL vs. Glargine 100 U/mL, Evaluated by the Low BG Index in Randomized Phase III Clinical Trials [J].

Kovatchev, Boris P. ;

Meng, Zhaoling ;

Breton, Marc D. ;

Leroy, Bruno ;

Cali, Anna .

DIABETES, 2017, 66 :A266-A266

[47] Reproducible fluctuation Low Blood Levels in Insulin Glargine 300 E/ml [J].

Becker, R. ;

Nowotny, I. ;

Teichert, L. ;

Bergmann, K. ;

Kapitza, C. .

INTERNIST, 2015, 56 :20-20

[48] Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? [J].

Buscemi, Silvio ;

Randazzo, Cristiana ;

Buscemi, Carola .

JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (06) :1595-1596

[49] INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES [J].

Munshi, Medha N. ;

Gill, Jasvinder ;

Chao, Jason ;

Nikonova, Elena V. ;

Patel, Meenakshi .

ENDOCRINE PRACTICE, 2018, 24 (02) :143-149

[50] Safety and efficacy of a pragmatic self-titration 1 unit/day (INSIGHT) algorithm for insulin glargine 300 U/mL (Gla-300) [J].

Yale, J. -F. ;

Harris, S. B. ;

Berard, L. ;

Groleau, M. ;

Javadi, P. ;

Stewart, J. .

DIABETOLOGIA, 2016, 59 :S440-S440

← 1 2 3 4 5 →